Immetas Therapeutics Inc. and GC Biopharma Corp. have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases. The collaboration combines Immetas’ proprietary platform for modulating innate immune pathways with GC Biopharma’s mRNA therapeutic and lipid nanoparticle (LNP) delivery platforms.